Alnylam Pharmaceuticals Inc
ALNY328.160USD
-3.080-0.93%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
43.25BMarket Cap
1010.56P/E TTM
More Details of Alnylam Pharmaceuticals Inc Company
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Inc Info
Ticker SymbolALNY
Company nameAlnylam Pharmaceuticals Inc
IPO dateMay 28, 2004
CEOGreenstreet (Yvonne L)
Number of employees2230
Security typeOrdinary Share
Fiscal year-endMay 28
Address675 W Kendall St
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142-1168
Phone16175518200
Websitehttps://www.alnylam.com/
Ticker SymbolALNY
IPO dateMay 28, 2004
CEOGreenstreet (Yvonne L)
Company Executives of Alnylam Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
+775.00%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
Other
61.62M
4.93%
By RegionUSD
Name
Revenue
Proportion
United States
613.98M
49.16%
Net revenues from collaborations
351.74M
28.16%
Europe
172.67M
13.82%
Rest of World
64.43M
5.16%
Royalty revenue
46.20M
3.70%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
Other
61.62M
4.93%
Shareholding Stats
Updated: 10 hours ago
Updated: 10 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
Other
54.86%
Shareholders
Shareholders
Proportion
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
Other
54.86%
Shareholder Types
Shareholders
Proportion
Investment Advisor
69.40%
Investment Advisor/Hedge Fund
23.27%
Hedge Fund
3.83%
Research Firm
2.50%
Sovereign Wealth Fund
1.70%
Pension Fund
1.30%
Bank and Trust
1.26%
Corporation
1.05%
Individual Investor
0.43%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1441
132.38M
102.07%
-8.88K
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
2023Q3
1103
121.13M
101.32%
-503.11K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
16.43M
12.44%
-370.75K
-2.21%
Sep 30, 2025
Fidelity Management & Research Company LLC
15.91M
12.04%
+854.66K
+5.68%
Sep 30, 2025
The Vanguard Group, Inc.
13.51M
10.22%
+267.08K
+2.02%
Sep 30, 2025
Capital Research Global Investors
7.22M
5.47%
+31.18K
+0.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.59M
4.98%
+52.87K
+0.81%
Sep 30, 2025
JP Morgan Asset Management
3.87M
2.93%
+2.07M
+115.83%
Sep 30, 2025
State Street Investment Management (US)
3.08M
2.33%
-91.63K
-2.89%
Sep 30, 2025
Baillie Gifford & Co.
2.79M
2.11%
-242.53K
-8.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.50M
1.89%
+100.47K
+4.19%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
View more
Global X Genomics & Biotechnology ETF
Proportion6.48%
ProShares Ultra Nasdaq Biotechnology
Proportion5.81%
Invesco Nasdaq Biotechnology ETF
Proportion5.77%
Franklin Genomic Advancements ETF
Proportion5.35%
iShares Biotechnology ETF
Proportion5.07%
VanEck Biotech ETF
Proportion4.56%
American Century Focused Dynamic Growth ETF
Proportion3.76%
Goldman Sachs Future Health Care Equity ETF
Proportion3.42%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.33%
Invesco NASDAQ Next Gen 100 ETF
Proportion3.28%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
